Jan 27, 2021 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia Learn More
Jan 12, 2021 Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia Learn More
Dec 28, 2020 Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Learn More
Dec 23, 2020 Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Learn More